The FDA’s new strategy to ensure that the safety of certain drugs outweighs the risks they potentially pose to patients continues to evolve as the healthcare industry takes an active role in current and future REMS requirements.
Examining issues regarding SCIG billing, coding and Medicare claims, along with questions about certification of homebound patients and products with new reimbursement codes.
With the push to reduce the cost of healthcare yet improve the quality and efficiency of care, Accountable Care Organizations could be a solution.
We're answering questions about switching from intravenous immune globulin therapy to subcutaneous immune globulin therapy, copayment for self-injectables, the definition of homebound patients and more.
While there has been virtually no decrease in the number of medical misdiagnoses in the U.S., awareness of the problem is growing, resulting in increased recommendations for reducing the incidence rate.
What effects can insurance companies, physicians, hospitals and the biopharmaceutical industry expect from the gradual implementation of healthcare reform law?
Discussing reimbursement codes and insurance coverage of Fluzone and off-label uses for Rituxan.
Clarifying some commonly held misunderstandings about healthcare reimbursement.
To err may be human, but when it comes to medication mistakes, the consequences can be deadly. Remedying the problem will require coordinated interventions across all sectors of the healthcare system.
The extensive process through which the FDA approved the 2009 H1N1 flu vaccine mirrors what is required for the licensure of seasonal flu vaccines
When it comes to preventing counterfeit drugs from tainting the supply chain, solutions are far from simple. Meaningful preventive measures will require education and legislation on federal and state levels, and within the industry itself.